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Human genetic defects in the growth hormone (GH)–IGF-I axis affecting the IGF system
present with growth failure as their principal clinical feature.This is usually associated with
GH insensitivity (GHI) presenting in childhood as severe or mild short stature. Dysmorphic
features andmetabolic abnormalitiesmay also be present.The ﬁeld of GHI due tomutations
affecting GH action has evolved rapidly since the ﬁrst description of the extreme phenotype
related to homozygous GH receptor (GHR) mutations in 1966. A continuum of genetic, phe-
notypic, and biochemical abnormalities can be deﬁned associated with clinically relevant
defects in linear growth. The mechanisms of the GH–IGF-I axis in the regulation of normal
human growth is discussed followed by descriptions of mutations in GHR, STAT5B, IGF-I,
IGFALS, IGF1R, andGH1 defects causing bio-inactive GH or anti-GH antibodies.These GH–
IGF-I axis defects are associated with a range of clinical, and hormonal characteristics. An
up-dated approach to the clinical assessment of the patient with GHI focusing on investi-
gation of the GH–IGF-I axis and relevant molecular studies contributing to the identiﬁcation
of causative genetic defects is also discussed.
Keywords: genetic defects, childhood linear growth, growth hormone insensitivity, growth hormone–IGF-I axis
mutations
INTRODUCTION
Human genetic defects in the growth hormone (GH) – IGF-I axis
causing disruption of the IGF system are usually associated with
GH insensitivity (GHI) due to the essential role of this system in
the regulation of GH action. GHI (OMIM #262500 and #245590)
was ﬁrst described in a pediatric setting by Laron et al. (1966),
with the description of extreme growth failure in siblings in a
consanguineous Jewish family who had the phenotype of hypopi-
tuitarism with high serum GH concentrations (Laron, 2004). For
many years this disorder was referred to as Laron syndrome and
was eventually shown to be caused by a defect in the GH receptor
(GHR) resulting in deﬁcient binding of 125I-GH to GHRs pre-
pared from the patients’ liver membranes (Eshet et al., 1984). This
striking but very rare phenotype, which was also untreatable at
that time, became synonymous with the diagnosis of GHI, a per-
ception that remained largely unchallenged for over 20 years. In
the late 1980s two pivotal developments brought key changes to
the ﬁeld. The ﬁrst was the synthesis and availability of recombi-
nant human IGF-I for therapy (Laron et al., 1988; Walker et al.,
1991), and the second was the advent of molecular techniques,
which led to the cloning, and characterization of the human GHR,
thus initiating the understanding of the pathophysiology of GHI
(Amselem et al., 1989; Godowski et al., 1989). The subsequent
study of genetic abnormalities in the GH–IGF axis has provided
invaluable information on the physiology of human linear growth.
In medicine, scientiﬁc advances often move more rapidly than
the practices of clinicians, who may remain attached to the rec-
ognized, and trusted view of a certain disorder, particularly if it
is rare. This has been the case with GHI, which is now known
not to be a single entity, but a broad diagnostic category compris-
ing a range of defects affecting the function of the IGF system.
These abnormalities may involve genes coding for proteins that
regulate GH binding or signal transduction and IGF-I synthesis,
transport, or action and are associated with a variety of pheno-
types and biochemical abnormalities presenting to the pediatric
endocrinologist. This review will describe the individual muta-
tions and discuss the investigation of the child with short stature
who has features suggesting the presence of a causative genetic
defect.
Previous reviews have often described the characteristics of
the extreme phenotype (Rosenfeld et al., 1994; Laron, 2004; Sav-
age et al., 2006), however we concentrate on defects illustrating
the range of phenotypes. The article discusses the genetic causes
of GHI, also referred to as primary IGF deﬁciency. We aim also
to up-date and orientate clinicians in the appropriate diagnostic
approach to children with growth failure.
THE GH–IGF AXIS IN HUMAN GROWTH
PHYSIOLOGY OF GH AND THE IGF-I SYSTEM IN RELATION TO LINEAR
GROWTH
The actions of GH are mediated by a combination of components
of the IGF system, including IGF-I, IGF-binding proteins (IGF-
BPs), the IGF-I receptor (IGFIR), and IGF-independent effects
through direct GH action. A diagram of the GH–IGF axis is shown
in Figure 1. The original“somatomedin hypothesis”proposed that
GH binding to its receptor stimulated IGF-I production, which
independently affected growth (Salmon and Daughaday, 1957).
Green et al. (1985) then proposed the “dual effector hypothesis”
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FIGURE 1 |The GH–IGF-I axis in human growth. Solid arrows,
activation processes; dashed arrows, translocation processes.
P, phosphorylated residue; Y, tyrosine; AKT, v-akt murine
thymoma viral oncogene homolog, also known as PKB, protein kinase B; ALS,
acid-labile subunit; IGFBP-3, IGF-binding protein-3; IGFIR, IGF-I receptor; JAK2,
Janus kinase 2; MAPK, mitogen-activated protein kinase; PI3K,
phosphatidylinositol 3-kinase; STAT, signal transducer and activator of
transcription.
suggesting that GH regulates the expression of locally produced
IGF-I, which then acts in an autocrine/paracrine manner. Expres-
sion of the IGF1 gene was found in multiple tissues throughout
embryonic and post-natal development (Roberts et al., 1987; Han
et al., 1988) and injection of GH into hypophysectomized rats
increased IGF1 mRNA in numerous non-hepatic tissues (Lowe
et al., 1987, 1988). Direct injection of GH into the cartilage
growth plate of hypophysectomized rats also resulted in signiﬁ-
cantly increased longitudinal bone growth (Isaksson et al., 1982).
These and other studies suggested that GH has local effects, inde-
pendent of those mediated by circulating “endocrine” IGF-I. This
hypothesis was extended by Isaksson and others (Nilsson et al.,
1986; Isaksson et al., 1987) who demonstrated that GH stimulated
differentiation of preadipocytes and chondrocytes in the growth
plate, while IGF-I stimulated their clonal expansion.
In a comprehensive review of the roles of GH and IGF-I, Le
Roith et al. (2001) presented a revised somatomedin hypothe-
sis, taking account of gene deletion experiments in mice that
questioned the role of liver IGF-I and its circulating endocrine
form in controlling post-natal growth and development (Sjö-
gren et al., 1999; Yakar et al., 1999). Liver-speciﬁc Igf1 knock-out
mice continued to grow normally despite reduction in circulat-
ing IGF-I, indicating that locally produced IGF-I was an impor-
tant growth mediator (Yakar et al., 1999). Le Roith has recently
modiﬁed his conclusions following data showing that when the
hepatic Igf1 transgene was able to elevate serum IGF-I levels
growth was largely restored (Wu et al., 2009). Kaplan and Cohen
(2007) further proposed the apparent paradox that GH exerts its
effects through IGFs, some of which oppose the known actions of
GH.
Studies using Igf1 knock-out mouse models have shown that
GH stimulates bone growth by IGF-I-independent and IGF-
I-dependent mechanisms. Some 75% of serum IGF-I is liver-
derived, while the remainder originates from non-hepatic tissues
(Sjögren et al., 1999;Yakar et al., 1999). In addition, serum levels of
the acid-labile subunit (ALS) and IGFBP-3 are important in main-
taining circulating IGF-I (Ohlsson et al., 2009). The importance
of ALS was shown in the Igfals knock-out mouse model (Ueki
et al., 2000) and by Domené et al. (2004) who reported the ﬁrst
homozygous mutation in human IGFALS causing severe IGF-I
deﬁciency.
EFFECTS OF HUMAN GH–IGF AXIS MUTATIONS ON LINEAR GROWTH
Normal GH secretion and the functional integrity of the IGF
system are essential for normal linear growth. Defects that have
been identiﬁed to cause impaired growth are shown in Table 1. A
summary of phenotypic and biochemical features in the range of
GH–IGF-I axis defects is given inTable 2.Humanpre-natal growth
is regulated principally by nutritional supplies, which inﬂuence
fetal IGF-I and, perhaps, IGF-II (Derr et al., 2011). Targeted dis-
ruption of either Igf1 or Igf2 in mice led to 40% reduction in fetal
growth (Milward et al., 2004). The importance of normal IGF-
I production in humans was conﬁrmed by the pre-natal growth
failure reported in patients with IGF1 mutations (Jin et al., 2008;
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Rowlinson et al., 2008). IGF-I action is also essential as demon-
strated by IGFIR rodent knock-out studies (Igf1r−/−) resulting in
55% reduction in fetal size (Milward et al., 2004), an effect also
present in humans with mutations of IGF1R (Barclay et al., 2010).
Post-natal growth may be disrupted by mutations that disturb
the functional integrity of the cascade of GH–GHR interaction,
GH signal transduction, and IGF-I production, transport, and
Table 1 | Genetic defects involving the IGF system and disrupting
linear growth.
Defects of the GH–IGF-I axis
GH receptor defects
Extracellular mutations
Transmembrane mutations
Intracellular mutations
GH signal transduction defects (STAT5b)
Mutations of SHP-2 (encoded by PTPN11)
IGF1 mutations or deletions
Defects causing IGF-I deﬁciency
Bio-inactive IGF-I
Acid-labile subunit gene defects
IGF-I receptor (IGFIR) gene mutations
GH neutralizing antibodies in patients with GH gene deletion
PTPN11, protein tyrosine phosphatase, non-receptor type 11; SHP-2, Src-
homology region 2-domain phosphatase-2; STAT, signal transducer and activator
of transcription.
action (Rosenfeld et al., 1994; Savage et al., 2006). In states of GHI
resulting from impaired GH–GHR function, IGF-I deﬁciency is
the cardinal biochemical feature. In mutations speciﬁcally involv-
ing the IGF1 or IGF1R, GHR function remains intact resulting
in possible accentuation of IGF-I-independent GH effects and
causing insulin resistance (Rowlinson et al., 2008).
MOLECULAR DEFECTS DISRUPTING THE IGF SYSTEM AND
CAUSING GROWTH FAILURE
THE GH RECEPTOR
The GHR protein mediates the effects of GH on linear growth
and metabolism. It is present ubiquitously, being most abundantly
expressed in the liver (Chia et al., 2010) and is composed of a large
extracellular domain involved in GH binding and GHR dimeriza-
tion, a single transmembrane domain that anchors the receptor
to the cell surface and an intracellular domain involved in GH
signaling. GH binding activates its receptor by inducing a confor-
mational change in a pre-existing GHR dimer (Adams et al., 2000;
Wang and Jiang, 2005), which promotes the binding of Janus tyro-
sine kinase 2 (JAK2) to a proline-rich Box 1 region located in the
proximal intracellular portion of the GHR (Fowden, 2003) and
initiates intracellular signaling.
Since 1966,more than 250 patients with genetic GHI have been
identiﬁed worldwide (Lupu et al., 2001; Savage et al., 2006). The
most severe phenotype was described by Laron et al., 1966; OMIM
#262500; Laron, 2004). Most GHI cases have autosomal reces-
sive inheritance and in the vast majority a molecular defect has
been identiﬁed involving homozygous or compoundheterozygous
mutations (Lupu et al., 2001). Over 70 mutations of GHR have
been identiﬁed to date ranging from deletions to point mutations
Table 2 | Summary of phenotypic and biochemical features in the range of GH–IGF-I axis defects.
Gene defect phenotype GHR STAT5b PTPN11 IGF-I IGFALS IGFIR Bio-inactive GH GH1 with anti-GH antibodies
Severe growth failure +/− + − + − − − +
Mild growth failure −/+ − + − + + + −
Mid-face hypoplasia +/− +/− − − − − − +
Other facial dysmorphism − − + + − + − −
Deafness − − − + − − − −
Microcephaly − − − + − + − −
Intellectual delay − − −/+ + − +/− − −
Puberty delay +/− +/− +/− − + − − −
Immune deﬁciency − + − − − − − −
Hypoglycemia + −/+ − − − − − −
Hyperinsulinemia − − − + + − − −
IGF-I deﬁciency + + −/+ +/− + − + +
IGFBP-3 deﬁciency + + −/+ − + − + +
ALS deﬁciency + + −/+ − + − + +
GH excess + + − +/− + − − −
GHBP deﬁciency +/− − − − − − − −
Homozygous or compound heterozygous
mutations
+ + − + + − −/+ +
Heterozygous mutations − − + − − + +/− _
+, positive; −, negative; +/−, predominantly positive; −/+, predominantly negative; ALS, acid-labile subunit; IGFBP-3, IGF-binding protein-3; GHBP, growth hormone
binding protein.
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including missense, nonsense, and splice mutations (Woods et al.,
1996a; Lupu et al., 2001; Savage et al., 2006). Among the defects
causing aberrant GHR splicing, an intronic base change leading
to the activation of a pseudoexon sequence and insertion of 36
new amino acids within the receptor extracellular domain was
ﬁrst reported in a consanguineous Pakistani family with mild GHI
(Metherell et al., 2001). This mutation leads to recognition of
the pseudoexon and inclusion of an additional 108 bases between
exons 6 and 7 leading to impaired function of the mutant protein
(Maamra et al., 2006). Intronic mutations resulting in pseudoexon
activation are rare in genetic diseases (Akker et al., 2007). The phe-
notypes occurring with this mutation range from severe to mild
growth failure (David et al., 2007).Amild phenotype of GHI is also
associatedwithheterozygousGHR mutations causing adominant-
negative effect (Ayling et al., 1997; Iida et al., 1998). These splice
site mutations (c.876− 1G>C) and (c.945+ 1G>A) form het-
erodimers with the wild-type GHR and exert a dominant-negative
effect on the normal protein.
Differing phenotypes within the same family may also occur,
as reported with one sibling having extreme growth failure (adult
height –8.7 SDS) and a second a milder phenotype (adult height
–6.0 SDS; Milward et al., 2004). Both siblings had the same
homozygous 22-bp deletion in the cytoplasmic domain of the
GHR, resulting in a frameshift and premature stop codon The
resultant GHR was truncated at amino acid 449 (GHR1-449) after
Box 1, the JAK2 binding domain of the receptor, and functional
studies inHEK293 andChinese hamster ovary cells showed a selec-
tive loss of STAT5 signaling in cells expressingGHR1-449 (Milward
et al., 2004).
A mild phenotype was also reported in two patients with
compound heterozygous mutations (Fang et al., 2007). Both had
undisputedGHIbut functional studies suggested incompleteGHR
defects that determined the phenotype by an additive effect of
each heterozygous mutation. A recent report described a child
and his mother with short stature and elevated GH binding pro-
tein (GHBP) levels associated with a novel heterozygous C→A
transversion at position c.785-3 at the acceptor site of intron 7
(Aalbers et al., 2009).
STAT5B MUTATIONS
STAT5B mutations present a characteristic phenotype combining
GHI and immunodeﬁciency (OMIM #245590). The binding of
GH to the GHR activates signaling cascades that include a number
of STAT pathways (STAT1, STAT3, STAT5a, and STAT5b). Molec-
ular defects in GH signal transduction pathways appear to be very
rare but recent identiﬁcation of human STAT5B mutations caus-
ing severe growth failure, IGF-I deﬁciency, andGHI,demonstrated
that STAT5b signaling is critical for GH-induced IGF-I production
and normal linear growth (Rosenfeld et al., 2007).
In 2003, the ﬁrst STAT5B mutation was identiﬁed in a 16-year-
old female from a consanguineous Argentine family (Kofoed et al.,
2003). Subsequent reports conﬁrmed that birth weight in affected
patients is generally normal, but is followed by severe post-natal
growth failure, with resistance to GH therapy (Hwa et al., 2005,
2007; Bernasconi et al., 2006; Vidarsdottir et al., 2006). The bio-
chemical proﬁle shows normal or elevated GH secretion, normal
GHBP values, and severe deﬁciencies of IGF-I, IGFBP-3, and ALS
which fail to increase on GH stimulation (Hwa et al., 2005, 2007;
Bernasconi et al., 2006; Vidarsdottir et al., 2006). A key feature in
all but one reported case (Vidarsdottir et al., 2006) was immune
dysfunction. In several patients, repeated pulmonary infections
occurred from infancy, including episodes of lymphoid interstitial
pneumonia (Kofoed et al.,2003;Hwaet al.,2007),a condition asso-
ciated with autoimmune disease. Interestingly, interferon-gamma
(IFNγ), a cytokine that signals predominantly through the STAT1
pathway, could also up-regulate IGF-I expression but only when
STAT5b was present and fully functional (Hwa et al., 2004).
The unusual combination of GHI and immune dysfunction in
the patient from Argentina led to the identiﬁcation of a homozy-
gous, missense, mutation in Exon 15 of the STAT5B gene (Kofoed
et al., 2003). The single G to C transversion at nucleotide 1888
of the STAT5B mRNA resulted in an Ala630 (GCT) to Pro (CCT)
substitution. Homology modeling with the solved structure of
STAT1 (Chen et al., 1998) showed that this mutation was within
the critical SH2 domain, a well-characterized, conserved, regu-
latory module that functions by interacting with high afﬁnity
to phosphotyrosine-containing target peptides. The Ala630Pro
(A630P) substitution was predicted to cause loss of thermody-
namic stability as well as aberrant folding and aggregation of the
mutant STAT5b protein (Chia et al., 2006). It is of note that path-
ogenic mutations in the SH2 domain of a number of cytoplasmic
signaling peptides, including STAT1, have been associated with
immuno-deﬁciencies, but none, except STAT5b, has been associ-
ated with severe growth retardation and IGF-I deﬁciency. Details
of the human STAT5B mutations reported to date are shown in
Figure 2.
Since the ﬁrst report, six other human STAT5B mutations have
been documented, with several found in siblings (Pugliese-Pires
et al., 2010). In contrast to mutations in IGF1 (see below), brain
development, and cognitive functions appeared to be normal.
The seven STAT5B mutations, located in different domains of the
STAT5b protein, comprise two missense mutations, p.A630P and
p.F646S, a nonsense mutation, p.R152X, single nucleotide inser-
tions, c.1191insG and c.1103insC, nucleotide deletions c.1680delG
and c.424_427del. The insertion/deletion mutations result in
frameshifts and truncation of the STAT5b protein. All reported
mutations were homozygous and autosomal recessive. The pheno-
type of STAT5b-deﬁcient patients includes profound short stature
anddelayed puberty in the older subjects. The only patientwithout
FIGURE 2 | Homozygous STAT5B mutations identified in patients with
GH insensitivity, IGF-I deficient, severely growth retarded, and
immune compromised. Schematic of the STAT5b protein modular
structure encoded by corresponding exons is as indicated. CCD,
coiled-coiled domain; DBD, DNA binding domain; L, linker; ND, N-terminal
domain; SH2, Src-homology 2-domain; STAT, signal transducer and activator
of transcription; TAD, transactivation domain.
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obvious immune deﬁciency, the ﬁrst reported male proband, con-
tracted hemorrhagic varicella at 16 years of age and had congenital
ichthyosis, but, otherwise, appeared healthy (Vidarsdottir et al.,
2006) One other patient was diagnosed with juvenile idiopathic
arthritis at the young age of 2 years. Immunological evaluations
reported for one of the patients carrying p.R152X, indicated lym-
phopenia and abnormally low regulatory T cells, similar to the
proband carrying the p.A630P mutation (Cohen et al., 2006). It
is also of note that STAT5b deﬁciency was associated with abnor-
mally high levels of circulating prolactin in six of the cases. It
remains unclear whether the hyperprolactinemia is a direct or
indirect consequence of STAT5B mutations.
IGF1 MUTATIONS
The ﬁrst human IGF1 defect was described byWoods et al., 1996b;
OMIM #608747 ). Features of patients with IGF-I defects are
shown in Table 3. The ﬁrst patient, a male, was born by Cae-
sarian section because of poor fetal growth. Placental weight was
diminished (350 g) and he had severe intrauterine growth retar-
dation (IUGR) with a birth weight of 1.4 kg (–3.9 SDS), birth
length of 37.8 cm (–5.4 SDS), and microcephaly (head circumfer-
ence 27 cm, –4.9 SDS). His growth failure worsened post-natally
and at 15.8 years, his height was 119.1 cm (–6.9 SDS), and his
weight was 23.0 kg (–6.5 SDS). He had delayed psychomotor
development and sensorineural deafness. During adolescence he
became insulin resistant. No IGF-I was detected in the serum even
after 4 days of stimulation with GH in an IGF-I generation test
(IGFGT). Spontaneous 12-hGHsecretion showed abnormally ele-
vated baseline and peaks. ALS and IGFBP-3 values were normal.
Molecular analysis revealed a homozygous deletion of exons 4 and
5 of the IGF1 gene. If translated, the resulting protein would be
severely truncated, lacking 45 of the 70 IGF-I amino acids (Woods
et al., 1996b). At 16.1 years (bone age, 14.2 years), recombinant
IGF-I therapy was initiated and resulted in beneﬁcial effects on
insulin sensitivity, body composition, bone size, and linear growth
(Camacho-Hübner et al., 1999; Woods et al., 2000).
Features of IUGR, microcephaly, retarded intellectual devel-
opment and severe post-natal growth failure were present in the
other cases with homozygous IGF1 mutations (Bonapace et al.,
2003; Walenkamp et al., 2005; Netchine et al., 2009). Deafness was
present in all the cases except the child with the mildest pheno-
type (Netchine et al., 2009). The microcephaly shown by these
patients, is a cardinal feature of the phenotype and allows a dis-
tinctionwith Russell–Silver syndrome patients,who have a relative
macrocephaly (Netchine et al., 2007). There has been some vari-
ation of serum IGF-I levels in the reported IGF1 mutation cases.
The third case to be described (Walenkamp et al., 2005) shared
an identical clinical phenotype with the index case (Woods et al.,
1996b), and had a younger brother with similar features who died
in childhood. This patient had a serum IGF-I level that was signiﬁ-
cantly increased (+7.3 SDS), explained by the fact that the patient’s
homozygous missense mutation of IGF1, a G→A nucleotide sub-
stitution at position 274, changing valine at position 44 in the A
domain of the mature IGF-I protein to methionine (p.V44M),
resulted in a recombinant protein (IGF1 V44M) which allowed
normal binding to IGFBP-3 but decreased afﬁnity (90-fold) for
its receptor, IGF1R. This patient therefore had bio-inactive IGF-I
caused by an IGF1 mutation. Serum IGF-I levels in the fourth
patient who had a relatively mild phenotype were also variable
and not severely decreased (Netchine et al., 2009). In all reported
subjects serum IGFBP-3 and ALS levels have been normal or
elevated.
Genetic analysis of IGF1 in the second case (Bonapace et al.,
2003) showed a homozygous T→A transversion in exon 6, that
would result if translated into an altered E domain of the IGF-I
precursor. It has been argued that this variant may be a poly-
morphism and thus not causative of the patient’s phenotype,
which was nevertheless strikingly similar to the other cases. In
the patient with the mild phenotype, sequencing of IGF1 revealed
a homozygous missense mutation resulting in the change of a
highly conserved arginine located in the C domain of the protein
into a glutamine (p.R36Q). Afﬁnity for the IGF1R decreased two
to threefold, resulting in decreased IGF1R autophosphorylation.
This partially diminished IGF-I activity had marked consequences
for fetal growth and development (Netchine et al., 2009).
IGFALS MUTATIONS
IGFALS mutations are associated with GHI and severe ALS and
IGF-I deﬁciencies (OMIM #601489). The ALS is a soluble protein
and member of the leucine-rich repeat family, and is expressed
by hepatocytes and secreted into the blood stream (Leong et al.,
1992). GH is the main inducer of ALS synthesis (Ooi et al., 1997)
and in the circulation ALS can be found free or bound to IGF-I or
-2 and IGFBP-3 or -5, to form a ternary complex (Baxter, 1994),
which prevents IGFs, free or bound to IGFBPs, from leaving the
circulation, thus prolonging their half-lives and decreasing their
availability at a tissue level. ALS is encoded by the IGFALS, located
on chromosome 16p13.3 and spanning 3.3 Kb. Inactivation of the
IGFALS in mice results in absence of circulating ALS but only
modest growth failure despite marked reduction of serum IGF-I
and IGFBP-3 levels (Ueki et al., 2000).
The ﬁrst patient with a homozygous mutation of IGFALS was
reported by Domené et al. (2004) and presented a new combi-
nation of genetic, biochemical, and phenotypic data. The most
striking feature of this genetic defect causingGHIwas amis-match
between extreme deﬁciencies of circulating IGF-I, IGFBP-3, and
ALS and relatively mild growth failure, even leading to a normal
adult height in some patients (Domené et al., 2007). A recent
review of published cases conﬁrms these features (Domené et al.,
2009). Sixteen different mutations of the human IGFALS gene
(Figure 3) have been identiﬁed in 21 cases (Domené et al., 2009).
Eleven were homozygous and six were compound heterozygous
with autosomal recessive inheritance. IGFALS mutations have
included missense and nonsense mutations, deletions, duplica-
tions, and insertions resulting in frameshift and premature stop
codons and in-frame duplication mutations leading to insertion
of extra amino acid residues (Domené et al., 2009). In all cases,
there was extreme deﬁciency of circulating ALS, with inability
to form the ternary complex (Domené et al., 2009; David et al.,
2010).Whereas circulating levels of IGF-I and IGFBP-3 are severely
reduced, due to their rapid clearance, local production of IGF-I in
peripheral tissues, notably the growth plate, appears to be pre-
served or even increased due to up-regulation of GH secretion
(Domené et al., 2004). Insulin resistance, with hyperinsulinemia
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Table 3 | Characteristics of six cases with IGF1 defects.
Woods et al.
(1996b)
Bonapace et al.
(2003)
Walenkamp et al.
(2005)
Netchine et al.
(2009)
van Duyven-
voorde et al.
(2010)
van Duyven-
voorde et al.
(2010)
OBSERVATION
Sex Male Male Male Male Female Male
Consanguinity Yes Yes Yes Yes No No
Birth weight (SDS/g) −3.9/1400 −4.0/1480 −2.5/1420 −2.5/2350 −2.9/2300 −1.2/3300
Birth length (SDS/cm) −5.4/37.8 −6.5/41 −3/39 −3.7/44 −3.8/44.0 −1.0/50.0
Cranial circumference (SDS/cm) −4.9/27 −7.5/26.5 −8.0/44.2 −2.5/32 −2.4/47.8 −1.6/49.0
Growth (SDS) −6.9 at
16 years
−6.2 at 1.6 years −9 at 55 years −4.5 at 3 years −4.1 at
8.2 years
−4.6 at
6.2 years
Microcephaly Yes Yes Yes Yes Yes Mild
Development delay Yes Yes Yes Mild Yes No
Deafness Yes Yes Yes No No No
Adiposity Yes No Yes No No No
HORMONAL EVALUATION
IGF-I levels Undetectable 1.0 ng/mL +7.3 SDS Variable −2.3 SDS −2.6 SDS
IGFBP-3 levels 3.3mg/L 3.6mg/L 1.98mg/L (+0.1 SDS) 4.3mg/L +1.2 SDS +0.1 SDS
Molecular defect Hom p.? (Del
ex 4–5)
Hom p.? ** Hom p.V44M Hom p.R36Q Het c.243−
246dupCAGC
Het c.243−
246dupCAGC
IGF1R afﬁnity Zero Not studied Extremely low Partially reduced Not studied Not studied
IGFBP-3, IGF-binding protein-3; SDS, standard deviation score; Hom, homozygous defect; Het, single heterozygous defect.
∗∗This mutation is localized within the polyadenylation site and alters mRNA splicing. The 3′ end of the resulting aberrant IGF-I transcript contains a partial sequence
from the downstream gene KIAA0537.
FIGURE 3 | Schematic representation of the ALS protein indicating the
location of identified human IGFALS mutations.The IGFALS is
composed of two exons, with ﬁve amino residues of the ALS signal peptide
encoded by exon 1 and the ﬁrst ﬁve amino residues of exon 2 and the
remainder of the ALS protein encoded by exon 2. ALS, acid-labile subunit;
NH2, N-terminal region.
and low IGFBP-1, has also been described in these patients (Heath
et al., 2008; Domené et al., 2009).
Recently attention has focused on the possible effect of het-
erozygous IGFALS mutations on growth. An analysis of 21
patients with homozygous or compound heterozygous IGFALS
mutations and their family members who were either heterozy-
gous carriers or homozygous wild-type normal has recently
been published (Fofanova-Gambetti et al., 2010). Mean height
SDS was –2.31± 0.87 in the homozygous IGFALS muta-
tion patients. Analyses within individual families showed that
heterozygosity for IGFALS mutations resulted in approxi-
mately 1.0 SD height loss in comparison with wild-type,
whereas homozygosity or compound heterozygosity resulted
in a further loss of 1.0–1.5 SD, suggestive of a gene-dosage
effect.
IGFIR MUTATIONS
IGFIR mutations are characterized by IGF-I resistance causing
impaired fetal and post-natal growth (OMIM #270450). The
IGF1R is a transmembrane receptor and belongs to the insulin
receptor family, which includes the IGF2R and insulin receptor.
The IGFIR is expressed widely and binds IGF-I and -2 with high
afﬁnity, mediating their biological actions by activating a complex
intracellular signaling cascade leading to the transcription of IGF
target genes. The IGF1R gene is located on chromosome 15q26.3
and spans 315 kb.
Mutations in IGF1R were ﬁrst reported by Abuzzahab et al.
(2003) following analysis of DNA from cohorts of children with
short stature and unexplained IUGR. The ﬁrst child was a com-
pound heterozygote for point mutations in exon 2 of the IGFIR
gene that altered the amino acid sequence to p.R108Q in one
allele and p.K115N in the other. She had a birth weight of –3.5
SD with childhood short stature and an adult height of –4.8 SD.
The second patient, a boy, had a heterozygous nonsense muta-
tion (p.R59X) that reduced the number of IGF1Rs on ﬁbroblasts.
He also had low birth weight (–3.5 SD) and birth length (–5.8
SD) with microcephaly and post-natal growth failure (height –3.8
SD) at age 14months and some additional dysmorphic features.
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Serum IGF-I levels were normal or elevated in both patients and
GH secretion was within normal limits.
There have been several reports of familial short stature due to
IGF1R mutations. A heterozygous mutation in the cleavage site of
the proreceptor of IGF1R was reported in a 6-year-old Japanese
girl and her mother (Kawashima et al., 2005) and the group of
Wit in Leiden described a mother and daughter with a heterozy-
gous missense mutation in the intracellular part of the IGF1R
(Walenkamp et al., 2006). A 9-year-old male patient (height –
3.6 SD), his sister (height –1.94 SD and IUGR), and his mother
(height –4.6 SDS) carried the same IGF1R mutation which was a
novel heterozygous 19-nucleotide duplication in exon 18 (Fang
et al., 2009). Functional studies in primary dermal ﬁbroblasts
derived from the patient and familymembers indicated that IGF1R
mRNAexpressed from themutant allele was degraded through the
nonsense-mediated mRNA decay pathway resulting in reduced
amount of wild-type IGF1R protein and, subsequently, dimin-
ished activation of the IGF1R pathway. A further female child
was reported with a heterozygous missense mutation in the highly
conserved N-terminal ﬁbronectin type III domain of IGF1R with
functional studies demonstrating impaired post-receptor IGF-I
signaling (Inagaki et al., 2007).
GH1 MUTATIONS CAUSING BIOLOGICALLY INACTIVE GH
Certain GH1 mutations cause biologically inactive GH resulting
in a form of GHI (OMIM #262650). A syndrome of biologically
inactive GH causing GHI and short stature was ﬁrst described by
Kowarski et al. (1978). The molecular basis of this apparently rare
cause of GHI was clariﬁed by Takahashi et al. (1996, 1997) who
reported two cases with heterozygous mutations in the GH1 gene.
The ﬁrst case was a boy with severe short stature (height −6.1 SD)
who had increased immunoassayable GH and IGF-I deﬁciency,
which responded, as did his growth, to exogenous hGH therapy.
The mutation was a single-base missense substitution (p.R77G)
in exon 4 of the GH1. However his normal stature father also
had the same mutation. Functional studies demonstrated that the
mutant GH molecule had higher binding afﬁnity for the GHR and
inhibited its activation by wild-type GH in a dominant-negative
fashion, thus impairing GH bioactivity. The second case was a girl
with similar endocrine features and short stature associated with a
heterozygous single-base change (A→G) causing a p.D112G sub-
stitution in GH1. More recently, a child with short stature (height
−3.6 SD at age 9 years) from a consanguineous Serbian family was
reported to have a homozygous missense mutation, C53S, of GH1
leading to the absence of the disulﬁde bridge Cys-53 to Cys-165 in
the GH molecule (Besson et al., 2005).
GH1 GENE DELETIONS (TYPE IA GH DEFICIENCY) WITH ANTI-GH
ANTIBODIES
A rare formof GHIoccurs due to acquiredGH-inhibiting antibod-
ies in a category of children with familial isolated GH deﬁciency
(IGHD; OMIM #262400; Cogan and Phillips, 2006). Autosomal
recessive IGHD, caused by gross deletions of the GH1, result in
severe IGHD (Type IA) with undetectable GH secretion (Phillips
et al., 1981). Such patients have severe post-natal growth fail-
ure with height usually <−4.5 SD. Most of the GH1 deletions
are 6.7, 7.0, or 7.6 kb in length, although several of 45 kb have
been reported (Proctor et al., 1998).Microdeletions and frameshift
mutations have also been reported (Baumann, 2002; Cogan and
Phillips, 2006; Alatzoglou and Dattani, 2010). IGHD patients with
homozygous deletions of the GH1 gene frequently develop anti-
GH antibodies during treatment with GH due to immunological
intolerance. However, variability of both antibody formation and
response to GH therapy may occur, even within families (Proctor
et al., 1998). Rare homozygous microdeletions and single base-
pair substitutions in the GH1 coding region have also resulted
in anti-GH antibody formation during GH therapy. The forma-
tion of anti-GH antibodies neutralizes the growth response to GH
therapy, resulting in a state of GHI associated with severe short
stature. Such patients may respond to therapy with recombinant
human IGF-I, which becomes the only effective management for
their growth failure (Riedl and Frisch, 2006).
THE INVESTIGATION OF GH–IGF-I AXIS MUTATIONS
The evaluation of a child with short stature and a possible GH–
IGF-I axis mutation should comply with the classical paradigm of
clinical assessment followedby general (i.e.,non-endocrine) inves-
tigations, hormonal assessment, and appropriate genetic analyses.
An algorithm showing key steps in the investigation of genetic
GH–IGF-I axis defects is shown in Figure 4. As advances in mol-
ecular endocrinology related to growth disorders progress, the
crucial importance of detailed phenotypic evaluation and doc-
umentation becomes increasingly important. The urge to obtain
a possible molecular diagnosis at the onset of the investigations
should be resisted until detailed clinical and endocrine evalu-
ation has been performed. Clinical assessment should include
enquiries about family history of growth disturbance, consanguin-
ity, birth weight and length, and recurrent infections (Savage et al.,
2010). Examination should speciﬁcally assess the presence of pos-
sible facial dysmorphic features and microcephaly in addition to
anthropometric evaluation (Cohen et al., 2008).
INVESTIGATIONS OF THE GH–IGF-I AXIS
Investigations of the GH–IGF-I axis consist of determination of
GH secretion and exploration of the IGF system. A GH provoca-
tion test is recommended unless the child has normal auxology or
a basal IGF-I level above the mean for age (Cohen et al., 2008). In a
child with clinical criteria of GHD, a peak GH level of <10 ng/mL
has traditionally been used to support this diagnosis (GrowthHor-
mone Research Society, 2000). Basal IGF-I levels should also be
determined, although these may be inﬂuenced by factors such as
age, nutrition, chronic illness, and puberty. In the initial assess-
ment, IGFBP-3 adds little, except in children under 3 years of age,
where low IGFBP-3 is helpful in the diagnosis of GHD (Cian-
farani et al., 2005). Reliable assay performance and appropriate
normative data (Juul et al., 1994, 1995) are essential for the use
of IGF-I and IGFBP-3 in clinical practice, and adjustment for sex,
age, puberty, and nutritional status is recommended.
A diagnosis of GHI follows from the demonstration of abnor-
mal auxology, normal GH secretion, and IGF-I deﬁciency. How-
ever, the pathogenesis will not have been elucidated from these
investigations. The nature of the defect can often be deﬁned by
additional measurement of IGFBP-3, ALS, and GHBP (Savage
et al., 2010). InGHR defects IGF-I, IGFBP-3,andALS are decreased
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FIGURE 4 | Algorithm showing key steps in the investigation of genetic GH–IGF-I axis defects. SD, standard deviation; IGHD, isolated growth hormone
deﬁciency; ALS, acid-labile subunit; IGFBP-3, IGF-binding protein-3.
(Burren et al., 1999), although the degree of abnormality can vary
with the type of mutation, which also inﬂuences GHBP levels. GH
secretion is elevated in most patients with severe IGF-I deﬁciency.
THE IGF-I GENERATION TEST
The principle behind the design of the IGFGT was that repeated
injections of GH induce measurable increases of IGF-I, IGFBP-
3, and ALS secretion. However, in GH deﬁciency patients, the
degree of IGF-I response did not convincingly predict the growth
response to GH therapy (Rosenfeld et al., 1981). Normative data
were not established and the test is not used for this purpose.
Interest in the IGFGT was renewed when molecular evidence of
GHI was demonstrated and subjects were selected for rhIGF-I
therapy. Criteria for diagnosis of GHI were deﬁned as: failure to
increase IGF-I and IGFBP-3 by >15 and 400 ng/mL, respectively
(Blum et al., 1994; Woods et al., 1997). However, as the spectrum
of GHI disorders expanded, these criteria are now too strict for
mildly affected subjects and even in severe GHI patients, post-GH
increases of IGF-I ranged from <20 to 58 ng/mL and of IGFBP-
3 from 95 to 1762 ng/mL (Rosenfeld, 2005). Attempts to reﬁne
the IGFGT for the diagnosis of milder GHI have demonstrated
that patients with idiopathic short stature produced a subnormal
response (Selva et al., 2003) and subjects with IGF-I deﬁciency
and normal GH secretion also had subnormal ability to generate
IGF-I (Midyett et al., 2010). However, additional sensitivity for the
diagnosis of GH resistance was not seen with a low-dose GH pro-
tocol (Buckway et al., 2001). A lack of reproducibility of IGF-I and
IGFBP-3 responses in the IGFGT has also been reported (Jorge
et al., 2002). For this reason genetic analysis and assessment of
the growth response to GH therapy, especially in patients without
the classical GHI phenotype, should be performed to conﬁrm GH
resistance. The principal value of the IGFGT is the conﬁrmation of
extreme or severe GHI (Rosenfeld et al., 1994; Woods et al., 1997).
GENETIC INVESTIGATIONS
The discussions above have indicated that genetic mutations in the
GH–IGF-I axis make a major contribution to the pathogenesis of
GHI. Following clinical and biochemical assessment and where a
genetic cause of short stature is expected from the family history,
DNA analysis for key candidate genes can conﬁrm a genetic diag-
nosis. A hierarchy and priority of molecular tests can be deﬁned
following careful clinical and biochemical assessment. Testing for
molecular defects in the GH–IGF-I axis is not commercially avail-
able at the present time. However, there are a number of academic
laboratories that perform DNA sequencing studies of the relevant
candidate genes. In vitro functional studies may also be neces-
sary to quantitate the degree of protein dysfunction, particularly
in cases with a milder phenotype. There are many components of
the GH and IGF signaling cascades that remain poorly understood
and are legitimate candidates for harboring signiﬁcant mutations
and/or deletions. Thus the absence of identiﬁable mutations in the
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candidate genes described above cannot rule out the possibility of
a molecular abnormality of the GH–IGF axis.
Ideally familymembers should also be tested. It is now clear that
members of the same family with the same mutations may have
differing phenotypes Milward et al., 2004). Additionally, for many
of the autosomal recessive disorders described above, the issue of
heterozygous expression remains of great interest and is worthy of
further study (Fofanova-Gambetti et al., 2010; van Duyvenvoorde
et al., 2010).
CONCLUSION
From the fundamental importance of the GH–IGF axis in human
linear growth, it follows that defects at many points in this axis
will result in growth impairment leading to short stature. The
key defects leading to GHI have been described and the range
of genetic, clinical, and biochemical abnormalities, both within
each genetic disorder and within the spectrum of GHI disorders
as a whole has been emphasized. GHI can no longer be con-
sidered to be a single clinical entity, as it was envisaged nearly
50 years ago. As new genetic defects leading to an expansion of
the ﬁeld of GHI are described, each new mutation will itself con-
tribute to the genetic and phenotypic continuum. Although the
precise etiology inmany childrenwith short stature remains uncer-
tain, the investigation of patients with abnormal growth should
be encouraged in order to improve diagnosis and contribute to
science.
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